- Home
- ALIT vs PHAR Comparison
ALIT vs PHAR Comparison
Compare ALIT & PHAR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ALIT | PHAR |
|---|---|---|
| Founded | 2017 | 1988 |
| Country | United States | Netherlands |
| Employees | N/A | N/A |
| Industry | Business Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 1.1B |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | ALIT | PHAR |
|---|---|---|
| Price | $1.90 | $16.81 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 2 |
| Target Price | $5.25 | ★ $38.00 |
| AVG Volume (30 Days) | ★ 13.7M | 27.8K |
| Earning Date | 02-19-2026 | 11-06-2025 |
| Dividend Yield | ★ 8.79% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 0.00 |
| Revenue | ★ $2,289,000,000.00 | $362,274,000.00 |
| Revenue This Year | N/A | $25.19 |
| Revenue Next Year | $1.56 | $4.47 |
| P/E Ratio | ★ N/A | $2,998.75 |
| Revenue Growth | N/A | ★ 26.78 |
| 52 Week Low | $1.82 | $7.50 |
| 52 Week High | $7.66 | $18.30 |
Technical Indicators
Market Signals| Indicator | ALIT | PHAR |
|---|---|---|
| Relative Strength Index (RSI) | 34.62 | 50.62 |
| Support Level | $1.90 | $16.61 |
| Resistance Level | $2.00 | $17.37 |
| Average True Range (ATR) | 0.09 | 0.70 |
| MACD | 0.00 | -0.09 |
| Stochastic Oscillator | 20.03 | 38.17 |
Price Performance
Historical ComparisonAbout ALIT Alight Inc.
Alight Inc is a technology-enabled services company delivering human capital management solutions to many of complex organizations. This includes the implementation and administration of employee benefits (e.g., health, wealth and leaves benefits) solutions, currently operates under one reportable segment, Employer Solutions. The Company completed the Divestiture of Alight's Professional Services segment and Alight's Payroll & HCM Outsourcing business within the Employer Solutions segment. The company operates in USA states and International market too.
About PHAR Pharming Group N.V.
Pharming Group is a biopharmaceutical company focused in transforming the lives of patients with rare, debilitating, and life-threatening diseases. The company is actively developing and commercializing a diverse portfolio of innovative treatments, including both biologics and small molecule therapies. Its commercial products are RUCONEST, approved for the treatment of acute attacks in adult and adolescent patients with hereditary angioedema, or HAE; and Joenja (leniolisib), a small-molecule kinase inhibitor, developed for the treatment of activated phosphoinositide 3-kinase delta syndrome.